105 related articles for article (PubMed ID: 15598784)
21. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics.
Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Wongkham S
Cancer; 2007 Jun; 109(12):2497-505. PubMed ID: 17487855
[TBL] [Abstract][Full Text] [Related]
23. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
24. The surgical learning curve for prostate cancer control after radical prostatectomy.
Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
[TBL] [Abstract][Full Text] [Related]
25. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
[TBL] [Abstract][Full Text] [Related]
26. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
Poulos CK; Daggy JK; Cheng L
Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
[TBL] [Abstract][Full Text] [Related]
28. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
29. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
30. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate.
Konety BR; Leman E; Vietmeier B; Arlotti J; Dhir R; Getzenberg RH
J Urol; 2000 Nov; 164(5):1812-8. PubMed ID: 11025775
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2 immunohistochemical detection in prostate cancer.
Sulik M; GuziĆska-Ustymowicz K
Rocz Akad Med Bialymst; 2002; 47():254-61. PubMed ID: 12533968
[TBL] [Abstract][Full Text] [Related]
34. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
Yang G; Timme TL; Frolov A; Wheeler TM; Thompson TC
Cancer; 2005 Mar; 103(6):1186-94. PubMed ID: 15712208
[TBL] [Abstract][Full Text] [Related]
35. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
36. Characterization of minute adenocarcinomas of prostate at radical prostatectomy.
Truskinovsky AM; Sanderson H; Epstein JI
Urology; 2004 Oct; 64(4):733-7. PubMed ID: 15491711
[TBL] [Abstract][Full Text] [Related]
37. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
38. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
39. Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.
Lievano G; Di Domenico D; Brown J; Bridges P; Rubenstein M; Shaw M; Guinan P
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):261-7. PubMed ID: 9228652
[TBL] [Abstract][Full Text] [Related]
40. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.
Ricciardelli C; Quinn DI; Raymond WA; McCaul K; Sutherland PD; Stricker PD; Grygiel JJ; Sutherland RL; Marshall VR; Tilley WD; Horsfall DJ
Cancer Res; 1999 May; 59(10):2324-8. PubMed ID: 10344737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]